HOUSE BILL NO. 4607

May 16, 2019, Introduced by Reps. Whitsett, Peterson, Elder, Yancey, Rendon, Hoitenga, Garza, Tate, Chirkun, Cambensy, Haadsma, Kennedy, Brenda Carter, Wozniak, Neeley, Coleman, Jones and Robinson and referred to the Committee on Health Policy.

A bill to amend 1978 PA 368, entitled

"Public health code,"

(MCL 333.1101 to 333.25211) by adding section 16279.

the people of the state of michigan enact:

Sec. 16279. (1) A licensee who orders a laboratory test for the presence of Lyme disease in a human patient shall order an enzyme-linked immunosorbent assay test and a western blot assay test and shall provide the patient or his or her legal representative with written materials on Lyme disease and testing for Lyme disease before the tests are performed. The written materials must include, but are not limited to, all of the following:

(a) Information on each of the following:

(i) Available treatment options for Lyme disease.

(ii) A list of physicians with expertise in treating Lyme disease.

(iii) The symptoms and complications that an individual who is diagnosed with Lyme disease may experience.

(b) A notice in substantially the following form:

"Your health care provider has ordered a laboratory test for the presence of Lyme disease for you. Current laboratory testing for Lyme disease can be problematic and standard laboratory tests often result in false negative and false positive results. If tested too early, you may not have produced enough antibodies to be considered positive because your immune response requires time to develop antibodies. If you are tested for Lyme disease and the results are negative, this does not necessarily mean that you do not have Lyme disease. If you continue to experience unexplained symptoms, you should contact your health care provider and inquire about the appropriateness of retesting or initial or additional treatment.".

(2) A licensee who prescribes, administers, or dispenses any of the following for the treatment of Lyme disease in a human patient is not subject to administrative action under sections 16221 and 16226:

(a) An oral long-term antibiotic.

(b) An intravenous antibiotic administered through a vascular access device.

Enacting section 1. This amendatory act takes effect 90 days after the date it is enacted into law.